#### CASE REPORT – OPEN ACCESS

International Journal of Surgery Case Reports 29 (2016) 108-112



Contents lists available at ScienceDirect

#### **International Journal of Surgery Case Reports**

journal homepage: www.casereports.com



## Subcutaneous metastases from early stage esophageal adenocarcinoma case report



Sujata Datta<sup>a</sup>, Juan A. Muñoz-Largacha<sup>b</sup>, Lei Li<sup>c</sup>, Grace (Qing) Zhao<sup>c</sup>, Virginia R. Litle<sup>b,\*</sup>

- a Boston University School of Medicine, 72 East Concord St, Boston, MA, 02118, United States
- <sup>b</sup> Department of Surgery, Division of Thoracic Surgery, United States
- <sup>c</sup> Boston University School of Medicine, Department of Pathology, United States

#### ARTICLE INFO

# Article history: Received 18 August 2016 Received in revised form 26 October 2016 Accepted 27 October 2016 Available online 29 October 2016

Keywords: Esophageal adenocarcinoma Subcutaneous metastases Esophagectomy Case report

#### ABSTRACT

The identification of subcutaneous metastatic lesions from primary visceral malignancies has increased over time, probably due to an increase in the awareness of their presentation and an increase in cancer survival times. Although the rate of subcutaneous metastases from breast,lung and colon cancer is more significant, the incidence of subcutaneous metastases from esophageal carcinomas is very low. These metastatic lesions usually present metachronously and may signify advanced disease and poor prognosis. We report three cases with early stage esophageal adenocarcinoma treated with surgery with curative intent presenting with subcutaneous metastases two months, two years and three years after their esophagectomy.

© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

#### 1. Introduction

Cutaneous metastases from visceral malignancies have been reported in 5–10% of cases [1–3]. Breast, lung and colon cancers are the tumors most likely to spread to the dermis and commonly present after the 6th decade of life [2]. In a large cohort of 838 patients with esophageal cancer, a rate of distant metastasis of approximately 20% was reported [4]. However, these metastatic lesions were most commonly seen in abdominal lymph nodes (45%), liver (35%) and lung (20%), with a significantly lower rate of 1% for metastatic lesions involving the skin [4].

Subcutaneous metastatic lesions have been reported to arise from both esophageal adenocarcinomas and squamous cell cancers. However, their presentation is very rare and their incidence may depend on the prevalence of the primary carcinoma, with esophageal adenocarcinoma being more common in white males, and squamous cell cancer more common in white women, blacks, and Asians [5].

The location of subcutaneous metastasis from esophageal carcinoma is variable. The scalp, neck and face have been reported as common locations [2,6,7], although metastatic lesions to the chest wall, back and axillary regions have been reported as well [6,8–10]. These lesions are indeed rare.

Associated factors predicting the risk for subcutaneous metastasis are not yet well known. However, poorly differentiated adenocarcinomas and the evidence of signet ring cell features may increase the risk of cutaneous spreading [11]. The identification of these pathological patterns after surgical resection may help in establishing the metastatic risk and may aid in the follow-up planning for this group of patients.

The overall prognosis and survival rates for esophageal adenocarcinoma is poor at 15% [5,12], although early stage tumors (T2N0M0 stage or less) have adequate cure rates of around 50% after surgical resection [13,14]. Patients with subcutaneous metastatic disease have a significantly poorer prognosis with reported survival rates of less than one year after the identification of metastatic lesions, and treatment is usually aimed to palliation through possible resection with chemotherapy and radiotherapy [7,15–17].

We describe three cases with early stage esophageal adenocarcinoma presenting with subcutaneous metastases between two months and three years after esophagectomy with curative intent.


#### 2. Presentation of cases

#### 2.1. Patient 1

A 61 year old man with a history of reflux esophagitis was evaluated for progressive dysphagia and 10% weight loss in three months. Endoscopy revealed long segment Barrett's esophagus and a fungating mass at the GE junction (Siewert II) nearly obstructing the lumen. Biopsies showed poorly differentiated adenocarcinoma with signet ring cell features (Fig. 1A). PET-CT showed a 4.6 cm hypermetabolic mass with standard uptake value (SUV) of 11.8 without evidence of lymph node or distant metastasis. He

<sup>\*</sup> Corresponding author. E-mail address: Virginia.litle@bmc.org (V.R. Litle).

S. Datta et al. / International Journal of Surgery Case Reports 29 (2016) 108–112



**Fig 1.** Biopsy showed an infiltrating poorly differentiated adenocarcinoma with signet ring cell features (arrow) (A). After chemoradiation therapy, the surgical resection specimen showed an 8.5 cm tumor bed involved by residual infiltrating poorly differentiated adenocarcinoma invading into the muscularis propria (B) with no regional lymph nodes involvement. Chest wall metastasis (C) and excisional biopsy demonstrated a metastatic poorly differentiated adenocarcinoma with signet ring cell features (arrow) (D) morphologically consistent with the esophageal tumor.

received neoadjuvant chemoradiation therapy with carboplatinum and taxotere and 50 Gy of external beam radiation in 25 fractions. Post-treatment PET-CT showed a 58% decrease in the SUV value and no evidence of distant disease. An open McKeown esophagectomy was performed. The final pathologic stage was T2N0M0 with no involvement of the 19 lymph nodes examined and no evidence of lymphovascular invasion (Fig. 1B). Two months later he presented with shortness of breath and a palpable 7 cm mass cephalad to a left chest tube scar (Fig. 1C). CT scan revealed the chest wall mass, a moderate sized left pleural effusion with no tumor cells on cytology, and pulmonary and hepatic metastases. The chest wall lesion was metastatic poorly differentiated adenocarcinoma morphologically similar to the patient's known esophageal cancer, also with signet cell features (Fig. 1D). The patient died one month later.

#### 2.2. Patient 2

A 69-year-old man with a long history of Barrett's esophagus was diagnosed with a distal esophageal (Siewert I) moderately to poorly differentiated adenocarcinoma. Endoscopic ultrasound showed a non-circumferential, non-obstructing mass with two malignant-appearing lymph nodes, which was staged as T2N1MX by endosonographic criteria. PET-CT showed a mild hypermetabolic area in the distal esophagus with SUV of 3.8 and no evidence of hypermetabolic lymph nodes or distant metastasis. This patient did not undergo neoadjuvant therapy prior to surgical resection with a minimally invasive Ivor Lewis esophagectomy. The final

pathologic stage was T1bN0M0 with 23 lymph nodes negative for metastasis and an absence of lympho-vascular involvement (Fig. 2A). Two years later he presented with a tender subcutaneous mass measuring  $2 \times 2 \times 1$  cm on his right temple. Biopsy evidenced metastatic moderate to poorly differentiated adenocarcinoma with similar morphology to the original tumor and positive stains for carcinoembryonic antigen (CEA) and mucin, as well as cytokeratin 7 (CK7), confirming an upper gastrointestinal source (Fig. 2B–D). PET-CT showed diffuse metastatic disease in the bones and lungs. He received palliative chemotherapy and died two months later.

#### 2.3. Patient 3

A 61-year-old man presented with progressive dysphagia and weight loss of 25 pounds in three months. Endoscopy revealed a non-circumferential mass 35 cm from the incisors. Biopsy demonstrated poorly differentiated adenocarcinoma with focal signet ring cell features (Fig. 3A). Endoscopic ultrasound was done showing a partially obstructing mass with clinical stage T3N0MX. PET-CT showed hypermetabolic activity at the gastroesophageal junction (Siewert II) with SUV of 9.6 and no evidence of metastatic disease. Induction chemoradiotherapy was done followed by an open McKeown esophagectomy. He had a complete pathologic response with 14 negative lymph nodes and no lymphovascular invasion in the pathology report. Approximately three years later the patient presented with a small nodule on his scalp, which was excised and identified as a poorly differentiated metastatic adenocarci-

#### Download English Version:

### https://daneshyari.com/en/article/5733321

Download Persian Version:

https://daneshyari.com/article/5733321

<u>Daneshyari.com</u>